Otsuka Plans $2.8 Billion IPO To Feed Global Expansion
This article was originally published in PharmAsia News
Executive Summary
Otsuka Holdings Co., the parent of Japanese drug maker Otsuka Pharmaceutical Co. Ltd., has scheduled its long-planned initial public offering for December 15
You may also be interested in...
Novartis Edges Out BMS In Japan With First-line Indication Approval For Tasigna Ahead Of Sprycel
TOKYO - The showdown between Novartis' Tasigna (nilotinib) and Bristol-Myer Squibb's Sprycel (dasatinib) for share of the chronic myeloid leukemia market has escalated in Japan as Tasigna received approval from Japan's Ministry of Health, Labor and Welfare Dec. 21 for first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia
Novartis Edges Out BMS In Japan With First-line Indication Approval For Tasigna Ahead Of Sprycel
TOKYO - The showdown between Novartis' Tasigna (nilotinib) and Bristol-Myer Squibb's Sprycel (dasatinib) for share of the chronic myeloid leukemia market has escalated in Japan as Tasigna received approval from Japan's Ministry of Health, Labor and Welfare Dec. 21 for first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia
Otsuka Looks To IPO To Fund Overseas Expansion
Otsuka Holdings, the parent company of Japan's fifth-largest pharmaceutical company Otsuka Pharmaceutical, could go public on the Tokyo Stock Exchange within the year